Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size. With Executive and Consultant Guides 2025-2029
Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. And now Artificial Intelligence is opening new doors. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding in two distinct segments. Find out how this new way of understanding cancer will change cancer diagnostics forever.
Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.
The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.
Table of Contents
1. Market Guides
1.1. Cancer Panel Market - Strategic Situation Analysis
1.2. Large Comprehensive Cancer Panel Market - Situation Analysis
1.3. Guide for Executives, Marketing, Sales and Business Development Staff
1.4. Guide for Management Consultants and Investment Advisors
1.5. Impact of Artificial Intelligence on Cancer Profiling Market
2. Introduction and Market Definition
2.1. What are Cancer Gene Panels and Profiling?
2.2. The Sequencing Revolution
2.3. Market Definition
2.3.1. Revenue Market Size
2.4. Methodology
2.4.1. Methodology
2.4.2. Sources
2.4.3. Authors
2.5. Perspective: Healthcare Spending
2.5.1. Global Healthcare Spending
2.5.2. Spending on Healthcare and Pharmaceuticals
2.5.3. Spending on Diagnostics
2.5.4. Important Role of Insurance for Medical Services
3. Market Overview
3.1. Players in a Dynamic Market
3.1.1. Academic Research Lab
3.1.2. Diagnostic Test Developer
3.1.3. Instrumentation Supplier
3.1.4. Chemical/Reagent Supplier
3.1.5. Pathology Supplier
3.1.6. Independent Clinical Laboratory
3.1.7. Public National/regional Laboratory
3.1.8. Hospital Laboratory
3.1.9. Physicians Office Lab (POLS)
3.1.10. Audit Body
3.1.11. Certification Body
3.2. Oncogenomics
3.2.1. Carcinogenesis
3.2.2. Chromosomes, Genes and Epigenetics
3.2.2.1. Chromosomes
3.2.2.2. Genes
3.2.2.3. Epigenetics
3.2.3. Cancer Genes
3.2.4. Germline vs Somatic
3.2.5. Gene Panels, Single Gene Assays and Multiplexing
3.2.6. Genomic Profiling
3.2.7. The Comprehensive Assay
3.2.8. Changing Clinical Role
3.2.9. The Cancer Screening Market Opportunity
3.3. Cancer Management vs. Diagnosis
3.3.1. The Role of Risk Assessment
3.3.2. Diagnosis
3.3.3. Managing
3.3.4. Monitoring
3.4. Phases of Adoption - Looking into The Future
3.5. Structure of Industry Plays a Part
3.5.1. Hospital Testing Share
3.5.2. Economies of Scale
3.5.2.1. Hospital vs. Central Lab
3.5.3. Physician Office Lab's
3.5.4. Physician's and POCT
3.6. Currently Available Large Comprehensive Assays
3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
3.7.1. Medicare Profile Pricing
3.7.2. Whole Exome Sequencing
4. Market Trends
4.1. Factors Driving Growth
4.1.1. Level of Care
4.1.2. Companion Dx
4.1.3. Immuno-oncology
4.1.4. Liability
4.1.5. The Aging Effect
4.2. Factors Limiting Growth
4.2.1. State of knowledge
4.2.2. Genetic Blizzard
4.2.3. Protocol Resistance
4.2.4. Regulation and coverage
4.3. Instrumentation and Automation
4.3.1. Instruments Key to Market Share
4.3.2. Bioinformatics Plays a Role
4.4. Diagnostic Technology Development
4.4.1. Next Generation Sequencing Fuels a Revolution
4.4.2. Single Cell Genomics Changes the Picture
4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4. CGES Testing, A Brave New World
4.4.5. Biochips/Giant magneto resistance based assay
5. Cancer Panels & Profiles Recent Developments
5.1. Recent Developments - Importance and How to Use This Section
5.1.1. Importance of These Developments
5.1.2. How to Use This Section
5.2. Foundation Medicine, Fulgent Genetics to Launch Germline Testing
5.3. Advanced Genomics APAC, 3BIGS Partner on Cancer Testing
5.4. Lucence Assay Gets Coverage for Advanced Solid Tumors
5.5. Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy
5.6. Roche CGP Assay Shows Concordance With Other NGS-Based Assays
5.7. Precede Biosciences Emerges From Stealth With $57M
5.8. Geneseeq Nabs CE Marks for Cancer Test Kits
5.9. Realm IDx Profiling Test Gets National Health Coverage in Japan
5.10. Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
5.11. Guardant Health Secures Coverage for Liquid Biopsy Profiling Test
5.12. Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling